Nordson earnings date
Nordson (ND1) Q3 2026 Earnings Report
DE:ND1 Q3 2026 EPS Results
- Actual EPS
- EUR 2.96
- Consensus EPS
- EUR 2.82
- Beat/Miss
- Beat by +EUR 0.14
- One Year Ago EPS
- EUR 2.49
DE:ND1 Q3 2026 Revenue Results
- Actual Revenue
- EUR 745.37M
- Expected Revenue
- EUR 710.56M
- Beat/Miss
- Beat by +EUR 34.81M
- YoY Revenue Growth
- +10.27%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 08/19/2026
- Time
- After Close
- Conference Call
- Wednesday, August 19, 2026
Nordson's next earnings date is estimated for December 15, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was broadly positive: the company reported record sales, record EBITDA and adjusted EPS, strong free cash flow and a materially increased backlog, and it raised full-year guidance. Segment performance was strong across the board with exceptional outperformance in Advanced Technology Solutions and solid showings in Medical & Fluid Solutions. Headwinds include a noncash mark-to-market charge, ongoing inflationary pressures, a divestiture that reduced comparable medical sales, and concentration of upside in a cyclical segment (ATS) that may face tougher comparables next year. Overall financial strength (cash generation, deleveraging, margins) and constructive guidance outweighed the limited headwinds.
Nordson raised its fiscal 2026 full‑year guidance to $3.035–$3.075 billion in sales and $11.80–$12.00 in adjusted diluted EPS (assuming current FX rates, i.e., neutral FX), citing 35% year‑over‑year backlog growth and sustained order‑entry momentum; the update follows a record Q3 (sales $818 million, +10% YoY; organic +12%), record Q3 adjusted EPS of $3.25 (a $0.10 beat, +19% YoY), record EBITDA of $262 million (32% of sales) and adjusted operating profit of $226 million (28% of sales), with strong cash generation (Q3 free cash flow $237 million; ~144% conversion of net income), cash on hand $113 million, net debt ~$1.6 billion and leverage of 1.7x, and an expected full‑year tax rate near 18%; management cited these metrics, plus YTD capex of $40 million and year‑to‑date shareholder returns ($137 million dividends, $159 million repurchases), as the basis for the upgraded outlook.
- Record Quarterly SalesThird-quarter sales of $818 million, a 10% increase year-over-year (prior year $742 million); included 12% overall organic growth and effectively neutral currency impact.
- All-Time Record ProfitabilityEBITDA of $262 million (all-time record), up 10% year-over-year, representing 32% of sales; adjusted operating profit of $226 million (28% of sales).
- Record Adjusted EPS and Strong GAAP ResultsAdjusted earnings per share of $3.25 (all-time record), up 19% year-over-year and $0.10 above the high end of guidance; GAAP net income of $153 million or $2.73 per share.
- Robust Cash Generation and DeleveragingFree cash flow of $237 million in the quarter, representing 144% conversion of net income (quarter); cash on hand $113 million and net debt approximately $1.6 billion with leverage ratio reduced to 1.7x.
- Backlog and Order MomentumBacklog up 35% year-over-year, broadly based across all three segments; management notes normal turnover (~6 months) and no elongation of lead times.
- Segment Outperformance — Advanced Technology Solutions (ATS)ATS achieved an all-time quarterly record: sales $220 million, up 28% year-over-year (31% organic); EBITDA $66 million, up 58% year-over-year with a 30% EBITDA margin (improved from 24%).
- Strong Medical & Fluid Solutions (MFS) PerformanceMFS sales of $231 million (quarterly record), up 5% year-over-year and ~11% organic growth (divestiture of medical contract manufacturing reduced comparable sales by ~6%); EBITDA $88 million (38% margin), up 6% year-over-year and improved sequential margins.
- Industrial Precision Solutions (IPS) StabilityIPS sales $367 million, up 5% year-over-year (3% organic); EBITDA $130 million (35% margin) demonstrating stability while management prioritizes growth and margin protection.
- Upgraded Full-Year GuidanceFull-year fiscal 2026 sales guidance raised to $3.035 billion–$3.075 billion and adjusted EPS guidance to $11.80–$12.00, based on sustained order strength and backlog.
- Lower Net Interest ExpenseNet interest expense of $20 million in the quarter, a decrease of over $5 million year-over-year due to deleveraging and lower borrowing costs.
DE:ND1 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Dec 15, 2026 | 2026 (Q4) | 3.15- | 2.76 | ― | ― |
| Aug 19, 2026 | 2026 (Q3) | 2.822.96 | 2.49 | 19.05% (+0.47) | |
| May 20, 2026 | 2026 (Q2) | 2.572.61 | 2.21 | 18.18% (+0.40) | |
| Feb 18, 2026 | 2026 (Q1) | 2.162.16 | 1.88 | 15.05% (+0.28) | |
| Dec 10, 2025 | 2025 (Q4) | 2.672.76 | 2.53 | 8.99% (+0.23) | |
| Aug 18, 2025 | 2025 (Q3) | 2.402.49 | 2.2 | 13.28% (+0.29) | |
| May 28, 2025 | 2025 (Q2) | 2.152.21 | 2.13 | 3.42% (+0.07) | |
| Feb 19, 2025 | 2025 (Q1) | 1.901.88 | 2.01 | -6.79% (-0.14) | |
| Dec 11, 2024 | 2024 (Q4) | 2.362.53 | 2.24 | 13.01% (+0.29) | |
| Aug 21, 2024 | 2024 (Q3) | 2.142.20 | 2.14 | 2.55% (+0.05) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


